Clinical Trials Logo

Stage IV Renal Cell Cancer clinical trials

View clinical trials related to Stage IV Renal Cell Cancer.

Filter by:

NCT ID: NCT00126659 Terminated - Clinical trials for Clear Cell Renal Cell Carcinoma

Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney Cancer

Start date: January 2006
Phase: Phase 2
Study type: Interventional

Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving sorafenib before and after surgery may be an effective treatment for kidney cancer. This phase II trial is studying how well sorafenib works in treating patients who are undergoing surgery for metastatic kidney cancer.

NCT ID: NCT00098618 Terminated - Clinical trials for Clear Cell Renal Cell Carcinoma

Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Start date: October 2004
Phase: Phase 2
Study type: Interventional

Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth or by blocking blood flow to the tumor. Interferon alfa may interfere with the growth of tumor cells and slow the growth of kidney cancer. Sorafenib may help interferon alfa kill more tumor cells by making tumor cells more sensitive to the drug. Giving sorafenib together with interferon alfa may kill more tumor cells. This phase II trial is studying how well giving sorafenib with interferon alfa works in treating patients with locally advanced or metastatic kidney cancer.

NCT ID: NCT00009919 Terminated - Clinical trials for Stage IV Renal Cell Cancer

SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment

Start date: December 2000
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of SU5416 in treating patients who have metastatic kidney cancer that has not responded to previous therapy with interleukin-2. SU5416 may stop the growth of kidney cancer by stopping blood flow to the tumor